Atopic Dermatitis: Beneath the Surface - Individualizing Care for Patients with Moderate-to-Severe Disease Activity Expired Pre-Test 1. Activation of which of these cell types is chiefly involved in the early pathogenesis of AD? a. Eosinophils b. Keratinocytes c. Mast cells d. Th2 cells e. Unsure 2. Which of the following atopic dermatitis symptoms do patients typically identify as the most bothersome? a. Oozing lesions b. Pruritus c. Skin dryness d. Skin redness e. Sleep disturbance f. Unsure 3. Which of the following is the mechanism of action of crisaborole? a. Blocks activation of protein kinase A to reduce the release of TNF-alpha b. Blocks PDE4 from degrading cAMP to reduce release of inflammatory proteins c. Stimulates production of PDE4 to block release of interleukin 14 d. Stimulates the NF-ĸB pathway to block release of TNF-alpha e. Unsure 4. A 10-year-old patient with mild/moderate AD is not responding adequately to an aggressive course of treatment with topical prescription therapy. What do guidelines recommend for the next step? a. Assess patient for adherence, comorbidities, and avoidance of irritants/triggers b. Initiate phototherapy c. Initiate suppressive immunosuppressant therapy d. Initiate treatment with a biologic therapy (dupilumab) e. Unsure 5. Which of the following is the main mechanism of action of dupilumab in the treatment of AD? a. Blocks the IgE pathway b. Blocks the IL-4/IL-13 pathway c. Blocks the interferon-gamma pathway d. Blocks the TNF-alpha pathway e. Unsure 6. Lydia R., a 19-year-old woman, was initially diagnosed with AD at age 4 years. She complains of being unable to sleep because of severe itch and discomfort. She has family history of atopy and asthma but no known food allergies. She reports trying over-the-counter agents, topical steroids, moisturizing, and wet wraps; she has tried topical immunosuppressants, corticosteroids, and azathioprine. How would you treat her now? a. Crisaborole b. Dupilumab c. Methotrexate d. Omalizumab e. Unsure 7. How confident are you in your ability to recommend appropriate therapy for your patients with moderate-to-severe AD? a. Not at all confident b. Somewhat confident c. Confident d. Highly confident CAPTCHAThis question is for testing whether or not you are a human visitor and to prevent automated spam submissions.